Alnylam Switches Attention To Access After Onpattro EU Okay
European approval is in the bag for Onpattro for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis but in a week where ICER has criticized the price of the RNAi drug in the US, Alnylam now has to navigate reimbursement talks on this side of the Atlantic.
You may also be interested in...
Unveiling its Phase III data showing both an all-cause mortality and cardiovascular hospitalization benefit, Pfizer thinks it can bring dramatic improvement in therapy for transthyretin cardiomyopathy.
US FDA still appears to be open, if not optimistic, about path towards broader label for patisiran, the first-of-its-kind targeted RNA-based therapy.